NGS

Roche AXELIOS 1 has officially been launched as a transformative next-generation sequencing platform designed to address critical bottlenecks in genomics and clinical research. Announced by the healthcare pioneer Roche on June 29, 2026, from Basel, this disruptive system marks a major leap forward for global laboratories. By providing an unmatched combination of accuracy, speed, flexibility, scalability, and cost efficiency, the platform enables research facilities to execute complex workflows with ease. The platform is the first in the industry to be powered by proprietary sequencing by expansion (SBX) technology. This innovative architecture allows end-to-end, same-day whole-genome sequencing in research workflows, translating to highly accurate genomic results within a matter of hours. The platform holds immense promise for expanding current research capabilities and laying down the foundations for a broad range of clinical applications down the road. According to an official statement, early access data shared over the past year has generated strong interest across the global sequencing community. Real-world validation has already been demonstrated through successful collaborations with leading scientific institutions, including the Hartwig Medical Foundation and Broad Clinical Labs. These collaborative studies confirmed that the platform delivers remarkable throughput alongside record-breaking speed and superior cost efficiency. The Core Technology Driving Roche AXELIOS 1 At the heart of the Roche AXELIOS 1 platform is its ability to convert standard DNA or RNA into high signal-to-noise polymers known as "Xpandomers". These Xpandomers are measured by a highly sophisticated sequencing instrument that utilizes a reusable complementary metal-oxide-semiconductor (CMOS) sensor filled with millions of nanopores. This advanced architectural engineering enables ultra-rapid, single-molecule sequencing alongside near real-time analysis capabilities. The underlying Sequencing by Expansion (SBX) technology relies on a refined biochemical process to encode the sequence of a target nucleic acid molecule. The resulting Xpandomers are approximately fifty times longer than the original molecule. By encoding the sequence information into high signal-to-noise reporters, the technology ensures minimal background noise when threaded through a nanopore, drastically elevating accuracy thresholds. To support the seamless integration of this technology, Roche is offering specialized library prep kits along with a free open-source bioinformatics analysis suite called XOOS. The system is intentionally built to accommodate other life sciences tools, guaranteeing broad compatibility across various research applications. This complements Roche's existing sequencing portfolio listed on the SIX Swiss Exchange, which includes KAPA sample preparation products, the automated AVENIO Edge system, and specialized AVENIO oncology assays developed with Foundation Medicine. Expanding Genomic Research with Roche AXELIOS 1 Highlighting the strategic impact of the launch, Matt Sause, CEO of Roche Diagnostics, noted that Roche AXELIOS 1 delivers a disruptive sequencing solution combining high accuracy with unprecedented scalability. He emphasized that its cost efficiency will allow the sequencing community to develop brand-new applications that were previously considered unfeasible. Ultimately, the system is designed to unlock new frontiers in personalized healthcare and improve our collective understanding of complex diseases. Technical Specifications and Architecture of AXELIOS 1 Feature / ComponentSpecification DetailsPlatform NameAXELIOS 1Core TechnologyProprietary Sequencing by Expansion (SBX)Surrogate Polymer TypeXpandomer (50x longer than original target molecule)Sensor ArchitectureReusable CMOS sensor featuring millions of nanoporesAnalysis TypeSingle-molecule sequencing with near real-time analysisWorkflow EfficiencyEnd-to-end, same-day whole-genome sequencingSoftware SuiteXOOS (Free open-source bioinformatics analysis suite)Market Segment AvailabilityTargeted research-focused facilities initially Ecosystem Integration and Portfolio Synergy Product / KitRole in Sequencing EcosystemKAPA KitsHigh-performance DNA and RNA library preparation & target enrichmentAVENIO Edge SystemWalk-away automated solution for KAPA kits (no programming required)AVENIO AssaysRobust oncology solutions (e.g., AVENIO Tumor Tissue CGP Automated RUO Kit)Foundation MedicineCollaborative partner for AVENIO Tumor Tissue CGP Automated RUO KitXOOS SuiteTailored open-source bioinformatics analysis suite for SBX technology

Tag: NGS

Roche AXELIOS 1: A Transformative Step for Next-Generation Sequencing Platforms Launched

Areas Covered

Discover More

Roche AXELIOS 1: A Transformative Step for Next-Generation Sequencing Platforms Launched

AstraZeneca Datroway EU Approval: CHMP Recommends Novel ADC for Metastatic Triple-Negative Breast Cancer

Merck KGaA Acquires Bio-Techne to Advance ProteinSimple and RNAscope Workflows in $11.3 Billion Deal

Pfizer Inc. Announces Milestone as FDA Approves Pfizer’s Ibrance Regimen for Advanced Breast Cancer Frontline Maintenance

Eli Lilly Completes Acquisition of Centessa Pharmaceuticals to Advance Orexin Receptor 2 Agonist Therapies

Gilead Trodelvy European Commission Approval Marks Historic First-Line Breast Cancer Advance